Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Feasibility of Shrinking Field Radiation Therapy through 18F-FDG PET/CT after 40 Gy for Stage III Non-Small Cell Lung Cancers

  • Ding, Xiu-Ping (Department of Radiation Oncology, Shandong's Key Laboratory of Radition Oncology) ;
  • Zhang, Jian (Department of Radiation Oncology, Cancer Hospital, Tianjin Medical University) ;
  • Li, Bao-Sheng (Department of Radiation Oncology, Shandong's Key Laboratory of Radition Oncology) ;
  • Li, Hong-Sheng (Department of Radiation Oncology, Shandong's Key Laboratory of Radition Oncology) ;
  • Wang, Zhong-Tang (Department of Radiation Oncology, Shandong's Key Laboratory of Radition Oncology) ;
  • Yi, Yan (Department of Radiation Oncology, Shandong's Key Laboratory of Radition Oncology) ;
  • Sun, Hong-Fu (Department of Radiation Oncology, Shandong's Key Laboratory of Radition Oncology) ;
  • Wang, Dong-Qing (Department of Radiation Oncology, Shandong's Key Laboratory of Radition Oncology)
  • Published : 2012.01.31
Download PDF
⟨ Previous Next ⟩

Abstract

Objective: To explore the feasibility of shrinking field technique after 40 Gy radiation through 18F-FDG PET/CT during treatment for patients with stage III non-small cell lung cancer (NSCLC). Methods: In 66 consecutive patients with local-advanced NSCLC, 18F-FDG PET/CT scanning was performed prior to treatment and repeated after 40 Gy. Conventionally fractionated IMRT or CRT plans to a median total dose of 66Gy (range, 60-78Gy) were generated. The target volumes were delineated in composite images of CT and PET. Plan 1 was designed for 40 Gy to the initial planning target volume (PTV) with a subsequent 20-28 Gy-boost to the shrunken PTV. Plan 2 was delivering the same dose to the initial PTV without shrinking field. Accumulated doses of normal tissues were calculated using deformable image registration during the treatment course. Results: The median GTV and PTV reduction were 35% and 30% after 40 Gy treatment. Target volume reduction was correlated with chemotherapy and sex. In plan 2, delivering the same dose to the initial PTV could have only been achieved in 10 (15.2%) patients. Significant differences (p<0.05) were observed regarding doses to the lung, spinal cord, esophagus and heart. Conclusions: Radiotherapy adaptive to tumor shrinkage determined by repeated 18F-FDG PET/CT after 40 Gy during treatment course might be feasible to spare more normal tissues, and has the potential to allow dose escalation and increased local control.

Keywords

References

  1. Belderbos JS, Heemsbergen WD, De Jaeger K, et al (2006). Final results of a Phase I/II dose escalation trial in non-small-cell lung cancer using three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys, 66, 126-34. https://doi.org/10.1016/j.ijrobp.2006.04.034
  2. Blackstock AW, Ho C, Butler J, et al (2006). Phase Ia/Ib chemoradiation trial of gemcitabine and dose-escalated thoracic radiation in patients with stage III A/B non-small cell lung cancer. J Thorac Oncol, 1, 434-40. https://doi.org/10.1097/01243894-200606000-00010
  3. Bradley J, Graham MV, Winter K, et al (2005). Toxicity and outcome results of RTOG 9311: a phase I-II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non-small-cell lung carcinoma. Int J Radiat Oncol Biol Phys, 61, 318-28. https://doi.org/10.1016/j.ijrobp.2004.06.260
  4. Britton KR, Starkschall G, Tucker SL, et al (2007). Assessment of gross tumor volume regression and motion changes during radiotherapy for non-small-cell lung cancer as measured by four-dimensional computed tomography. Int J Radiat Oncol Biol Phys, 68, 1036-46. https://doi.org/10.1016/j.ijrobp.2007.01.021
  5. Curran WJ, Scott CB, Langer CJ, et al (2003). Long-term benefit is observed in a phase III comparison of sequential vs. concurrent chemo-radiation for patients with unresectable NSCLC: RTOG 9410. Proc Am Soc Clin Oncol, 22, 621a (abstract 2499).
  6. Eschmann SM, Friedel G, Paulsen F, et al (2007). Repeat 18F-FDG PET for monitoring neoadjuvant chemotherapy in patients with stage lll non-small cell lung cancer. Lung cancer, 55, 165-71. https://doi.org/10.1016/j.lungcan.2006.09.028
  7. Fox J, Ford E, Redmond K, et al (2009). Quantification of tumor volume changes during radiotherapy for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys, 74, 341-8. https://doi.org/10.1016/j.ijrobp.2008.07.063
  8. Gillham C, Zips D, Pönisch F, et al (2008). Additional PET/CT in week 5-6 of radiotherapy for patients with stage III non-small cell lung cancer as a means of dose escalation planning? Radiother Oncol, 88, 335-41. https://doi.org/10.1016/j.radonc.2008.05.004
  9. Gilman MD, Aquino SL (2005). State-of-the-art FDG-PET imaging of lung cancer. Semin Roentgenol, 40, 143-53. https://doi.org/10.1053/j.ro.2005.01.008
  10. Guckenberger M, Wilbert J, Richter A, et al (2011). Potential of adaptive radiotherapy to escalate the radiation dose in combined radiochemotherapy for locally advanced nonsmall cell lung cancer. Int J Radiat Oncol Biol Phys, 79, 901-8. https://doi.org/10.1016/j.ijrobp.2010.04.050
  11. Hong R, Halama J, Bova D, et al (2007). Correlation of PET standard uptake value and CT window-level thresholds for target delineation in CT-based radiation treatment planning. Int J Radiat Oncol Biol Phys, 67, 720-6. https://doi.org/10.1016/j.ijrobp.2006.09.039
  12. Kim TH, Cho KH, Pyo HR, et al (2005). Dose-volumetric parameters of acute esophageal toxicity in patients with lung cancer treated with three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys, 62, 995-1002. https://doi.org/10.1016/j.ijrobp.2004.12.025
  13. Kim TY, Yang SH, Lee SH, et al (2002). A phase III randomized trial of combined chemoradiotherapy versus radiotherapy alone in locally advanced non-small-cell lung cancer. Am J Clin Oncol, 25, 238-43. https://doi.org/10.1097/00000421-200206000-00007
  14. Kim YS, Yoon SM, Choi EK, et al (2005). Phase II study of radiotherapy with three-dimensional conformal boost concurrent with paclitaxel and cisplatin for stage IIIB nonsmall- cell lung cancer. Int J Radiat Oncol Biol Phys, 62, 76-81. https://doi.org/10.1016/j.ijrobp.2004.09.038
  15. Kong FM, Ten Haken RK, Schipper MJ, et al (2005). High-dose radiation improved local tumor control and overall survival in patients with inoperable/unresectable non-small-cell lung cancer: long term results of a radiation dose escalation study. Int J Radiat Oncol Biol Phys, 63, 324-33. https://doi.org/10.1016/j.ijrobp.2005.02.010
  16. Kupelian PA, Ramsey C, Meeks SL, et al (2005). Serial megavoltage CT imaging during external beam radiotherapy for non-small-cell lung cancer: observations on tumor regression during treatment. Int J Radiat Oncol Biol Phys, 63, 1024-8. https://doi.org/10.1016/j.ijrobp.2005.04.046
  17. Li BS, Gong HY, Huang W, et al (2011). Phase I Study of Pemetrexed, Cisplatin, and Concurrent Radiotherapy in Patients With Locally Advanced Non-small Cell Lung Cancer. Am J Clin Oncol [Epub ahead of print].
  18. MacManus M, Nestle U, Rosenzweig KE, et al (2009). Use of PET and PET/CT for radiation therapy planning: IAEA expert report 2006-2007. Radiother Oncol, 91, 85-94. https://doi.org/10.1016/j.radonc.2008.11.008
  19. Nestle U, Kremp S, Grosu AL (2006). Practical integration of [18F]-FDG-PET and PET-CT in the planning of radiotherapy for non-small cell lung cancer (NSCLC): the technical basis, ICRU-target volumes, problems, perspectives. Radiother Oncol, 81, 209-25. https://doi.org/10.1016/j.radonc.2006.09.011
  20. Nestle U, Walter K, Schmidt S, et al (1999). 18F-deoxyglucose positron emission tomography (FDG-PET) for the planning of radiotherapy in lung cancer: high impact in patients with atelectasis. Int J Radiat Oncol Biol Phys, 44, 593-7. https://doi.org/10.1016/S0360-3016(99)00061-9
  21. Rengan R, Rosenzweig KE, Venkatraman E, et al (2004). Improved local control with higher doses of radiation in large-volume stage III non-small cell lung cancer. Int J Radiat Oncol Biol Phys, 60, 741-7. https://doi.org/10.1016/j.ijrobp.2004.04.013
  22. Seppenwoolde Y, Muller SH, Theuws JC, et al (2000). Radiation dose-effect relations and local recovery in perfusion for patients with non-small-cell lung cancer. Int J Radiat Oncol Biol Phys, 47, 681-90. https://doi.org/10.1016/S0360-3016(00)00454-5
  23. van Baardwijk A, Bosmans G, Boersma L, et al (2007). PETCT-based auto-contouring in non-small-cell lung cancer correlates with pathology and reduces interobserver variability in the delineation of the primary tumor and involved nodal volumes. Int J Radiat Oncol Biol Phys, 68, 771-8. https://doi.org/10.1016/j.ijrobp.2006.12.067
  24. Willner J, Baier K, Caragiani E, et al (2002). Dose, volume, and tumor control prediction in primary radiotherapy of non-small cell lung cancer. Int J Radiat Oncol Biol Phys, 52, 382-9. https://doi.org/10.1016/S0360-3016(01)01823-5
  25. Woodford C, Yartsev S, Dar AR, et al (2007). Adaptive radiotherapy planning on decreasing gross tumor volumes as seen on megavoltage computed tomography images. Int J Radiat Oncol Biol Phys, 69, 1316-22. https://doi.org/10.1016/j.ijrobp.2007.07.2369

Cited by

  1. Staging with PET-CT in Patients with Locally Advanced Non Small Cell Lung Cancer is Superior to Conventional Staging Methods in Terms of Survival vol.14, pp.6, 2013, https://doi.org/10.7314/APJCP.2013.14.6.3743
  2. Clinical Outcome of Helical Tomotherapy for Inoperable Non-Small Cell Lung Cancer: The Kyung Hee University Medical Center Experience vol.15, pp.4, 2014, https://doi.org/10.7314/APJCP.2014.15.4.1545
  3. Potential Impact of Atelectasis and Primary Tumor Glycolysis on F-18 FDG PET/CT on Survival in Lung Cancer Patients vol.15, pp.9, 2014, https://doi.org/10.7314/APJCP.2014.15.9.4085
  4. Differences in the Prognostic Significance of the SUVmax between Patients with Resected Pulmonary Adenocarcinoma and Squamous Cell Carcinoma vol.15, pp.23, 2014, https://doi.org/10.7314/APJCP.2014.15.23.10171
  5. Feasibility of Image-Guided Radiotherapy and Concurrent Chemotherapy for Locally Advanced Nonsmall Cell Lung Cancer vol.33, pp.3, 2015, https://doi.org/10.3109/07357907.2014.1001896
  6. Late-Course Adaptive Adjustment Based on Metabolic Tumor Volume Changes during Radiotherapy May Reduce Radiation Toxicity in Patients with Non-Small Cell Lung Cancer vol.12, pp.1, 2017, https://doi.org/10.1371/journal.pone.0170901
  7. Role of interim 18F-FDG-PET/CT for the early prediction of clinical outcomes of Non-Small Cell Lung Cancer (NSCLC) during radiotherapy or chemo-radiotherapy. A systematic review vol.44, pp.11, 2017, https://doi.org/10.1007/s00259-017-3762-9